A61J1/05

MEDICATION KIT
20230172772 · 2023-06-08 ·

A medication kit for treating a health condition of a patient is provided. The medication kit includes a plurality of medicinal agents for treating a plurality of symptoms associated with the health condition. Each of the plurality of medicinal agents is adapted to treat one or more symptoms out of the plurality of symptoms. The medication kit further includes a plurality of containers for storing the plurality of medicinal agents. Each container stores one of the plurality of the medicinal agents.

Dialysis precursor composition

The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water, a sodium containing concentrate, and a bicarbonate containing concentrate into a ready-for-use dialysis solution. Said dialysis acid precursor composition consists of powder components comprising glucose, at least one dry acid and at least one calcium salt, and optionally potassium salt, and magnesium salt. According to the invention said glucose and said at least one calcium salt, are present as anhydrous components in said dialysis acid precursor composition.

Dialysis precursor composition

The present invention concerns a dialysis acid precursor composition for use during preparation of a dialysis acid concentrate solution and for mixing with water, a sodium containing concentrate, and a bicarbonate containing concentrate into a ready-for-use dialysis solution. Said dialysis acid precursor composition consists of powder components comprising glucose, at least one dry acid and at least one calcium salt, and optionally potassium salt, and magnesium salt. According to the invention said glucose and said at least one calcium salt, are present as anhydrous components in said dialysis acid precursor composition.

RFID TAG FOR ITS ARRANGEMENT ON A BLOOD-DERIVATED PRODUCTS BOTTLE AND USE OF THE SAME

An RFID tag is for arrangement on a bottle for blood-derived products. The bottle includes a main body, the upper end of which includes a neck. The bottle is hermetically sealed by a cap arranged in the upper portion of the neck. The upper portion of the cap includes at least two through-pipes and at least two stiffening ribs that are each connected to the pipes by one of the respective ends thereof. The RFID tag has at least two openings shaped to fit each of the through-pipes, respectively, of the cap such that said RFID tag is positioned on the upper surface of the cap and thus overcomes the obstacle of the through-pipes and the respective stiffening ribs.

Compositions and kits useful for treatment of respiratory illness

A stable liquid composition contained in a bottle wherein the composition comprises from about 0.001% to about 0.5% of phenylephrine hydrochloride, by weight of the stable liquid composition. The composition comprises less than about 0.1% of total aldehydes, by weight of the stable liquid composition, and has a pH from about 2 to about 6.5. The bottle comprises a material selected from polyethylene terephthalate (PET), glycol-modified polyethylene terephthalate (PETG), oriented polypropylene (OPP), polyvinylchloride (PVC), polyvinylidene chloride (PVDC), nylon, polyethylene terephthalate polyester (PETP), or combinations thereof.

Compositions and kits useful for treatment of respiratory illness

A stable liquid composition contained in a bottle wherein the composition comprises from about 0.001% to about 0.5% of phenylephrine hydrochloride, by weight of the stable liquid composition. The composition comprises less than about 0.1% of total aldehydes, by weight of the stable liquid composition, and has a pH from about 2 to about 6.5. The bottle comprises a material selected from polyethylene terephthalate (PET), glycol-modified polyethylene terephthalate (PETG), oriented polypropylene (OPP), polyvinylchloride (PVC), polyvinylidene chloride (PVDC), nylon, polyethylene terephthalate polyester (PETP), or combinations thereof.

Injection Vial and Injection Vial Management System
20220058456 · 2022-02-24 ·

An injection vial and injection vial management system is disclosed, wherein the injection vial is filled with a liquid medicine and signally connected with a blockchain network. The injection vial includes a bottle body and a chipset disposed within the bottle body. The chipset includes an identification label and a blockchain module. The identification label records a manufacturing process, a logistic process and a use process. The blockchain module signal connects to the blockchain network in order to record the manufacturing process, logistic process and use process in the blockchain network.

Injection Vial and Injection Vial Management System
20220058456 · 2022-02-24 ·

An injection vial and injection vial management system is disclosed, wherein the injection vial is filled with a liquid medicine and signally connected with a blockchain network. The injection vial includes a bottle body and a chipset disposed within the bottle body. The chipset includes an identification label and a blockchain module. The identification label records a manufacturing process, a logistic process and a use process. The blockchain module signal connects to the blockchain network in order to record the manufacturing process, logistic process and use process in the blockchain network.

Methods and apparatus for reducing contamination in blood draw samples
11253180 · 2022-02-22 · ·

Methods and apparatus are provided for increasing compliance with the discard volume method of blood drawing. The method includes attaching an initial discard container for discarding an initial amount of blood drawn to a standard blood culture bottle. The apparatus, detachable and configurable with a variety of standard blood culture containers, may act as a physical reminder and a convenient handling arrangement for drawing blood according to the preferred discard volume method that reduces sample contamination and false positives. These methods and apparatus may be compatible or retrofit with existing standard blood culture bottles or kits.

Parenteral nutrition formulation

The present disclosure relates to parenteral nutrition formulations, including ready-to-use parenteral nutrition formulations which are reconstituted from multi-chamber containers and amino acid formulations. More particularly, the present disclosure is directed to formulations comprising butyrate derivatives, specifically arginine butyrate, for use with adult or pediatric patients. The disclosure further provides for methods of reducing or preventing systemic and local inflammation of patients receiving parenteral nutrition, and methods of maintaining or ameliorating their systemic immunity and local immunity, as well as the patients' gut barrier functions.